Small molecule · developed by Anavex Life Sciences
Blarcamesine (ANAVEX2-73) is an oral drug studied in Rett syndrome and Alzheimer disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04304482 | Phase 2/3 | Rett Syndrome | Completed | AVXL |
| NCT04314934 | Phase 2/3 | Alzheimer Disease | Completed | AVXL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer DiseaseRett Syndrome
See AVXL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AVXL catalysts and pipeline →